Metformin Stada

Metformin, the active ingredient in Metformin Stada, is a biguanide presented as an oral tablet of unspecified strength for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, where it helps lower elevated blood glucose levels by reducing hepatic glucose output and enhancing peripheral insulin sensitivity.

GNH USA supplies Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets across the European Union and beyond.

Metformin Stada is used in the antidiabetic drug class to improve glycemic control in several metabolic conditions.

Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels. Prediabetes: helps delay progression to overt diabetes when combined with lifestyle measures. Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformin Stada may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Metallic taste - Loss of appetite - Vomiting

Serious or Rare Side Effects: - Lactic acidosis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic failure - Vitamin B12 deficiency - Hypoglycemia when combined with insulin or sulfonylureas - Acute pancreatitis

When prescribing Metformin Stada, clinicians should observe several precautionary measures to ensure patient safety.

Renal function: assess eGFR before initiation and periodically thereafter. Hepatic function: evaluate liver enzymes as impaired function increases lactic acidosis risk. Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia. Concomitant alcohol: limit intake to reduce lactic acidosis potential. Elderly patients: start at lower dose and monitor tolerance. Store at ambient temperature: keep in original container, protect from moisture.

Metformin Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: risk of acute renal failure and lactic acidosis; avoid concurrent use. - Cimetidine: may increase metformin plasma concentrations. - Alcohol abuse: heightens lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (especially thiazides): can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function. - NSAIDs: may reduce renal perfusion, increasing metformin levels. - Warfarin: may require INR monitoring.